Limits...
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S, TYSABRI Observational Program (TOP) Investigato - J. Neurol. Neurosurg. Psychiatr. (2014)

Bottom Line: Follow-up for at least 4 years from natalizumab commencement in 468 patients and at least 2 years in 2496 patients revealed no new safety signals.Mean EDSS scores remained unchanged up to 5 years.NCT00493298.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, Box Hill Hospital, Monash University, Victoria, Victoria, Australia.

Show MeSH

Related in: MedlinePlus

Annualised relapse rate on natalizumab therapy: per yearly interval over time (n=4821). Error bars indicate 95% CIs. Data beyond 5 years are excluded.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215289&req=5

JNNP2013306936F1: Annualised relapse rate on natalizumab therapy: per yearly interval over time (n=4821). Error bars indicate 95% CIs. Data beyond 5 years are excluded.

Mentions: Overall, the annualised relapse rate (95% CI) decreased from 1.99 (1.95 to 2.03) in the 12 months prior to baseline to 0.31 (0.29 to 0.32) on natalizumab therapy (p<0.0001). Relapse rates in each year of natalizumab exposure ranged from 0.21 to 0.30 (figure 1).


Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S, TYSABRI Observational Program (TOP) Investigato - J. Neurol. Neurosurg. Psychiatr. (2014)

Annualised relapse rate on natalizumab therapy: per yearly interval over time (n=4821). Error bars indicate 95% CIs. Data beyond 5 years are excluded.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215289&req=5

JNNP2013306936F1: Annualised relapse rate on natalizumab therapy: per yearly interval over time (n=4821). Error bars indicate 95% CIs. Data beyond 5 years are excluded.
Mentions: Overall, the annualised relapse rate (95% CI) decreased from 1.99 (1.95 to 2.03) in the 12 months prior to baseline to 0.31 (0.29 to 0.32) on natalizumab therapy (p<0.0001). Relapse rates in each year of natalizumab exposure ranged from 0.21 to 0.30 (figure 1).

Bottom Line: Follow-up for at least 4 years from natalizumab commencement in 468 patients and at least 2 years in 2496 patients revealed no new safety signals.Mean EDSS scores remained unchanged up to 5 years.NCT00493298.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia Department of Neurology, Box Hill Hospital, Monash University, Victoria, Victoria, Australia.

Show MeSH
Related in: MedlinePlus